The current contract arrangements for the supply of imported immunoglobulin products commenced on 1 January 2021. Those arrangements included provisions for some additional products to be added as they became available. The National Blood Authority is now pleased to announce that a new imported intravenous immunoglobulin (IVIg) product, Kiovig 10% (Takeda), will be available to order from Lifeblood from 1 May 2023.
What will be changing?
Kiovig, a 10% concentration IVIg product supplied by Takeda, will be available for supply under the National Blood Supply arrangements from 1 May 2023. This change is occurring to strengthen and diversify the supply of Ig in Australia to ensure eligible patients continue to have access to Ig treatment.
This will be in addition to the currently available suite of imported IVIg products, namely Privigen 10%, Flebogamma 10%, Gamunex 10%, Octagam 10%, Flebogamma 5% and the new domestic IVIg product Privigen AU.
What Approved Health Providers need to do
- Add the Kiovig 10% product codes (found below under ‘useful resources’) to your laboratory management system to allow you to receive the products into your stock.
- Distribute this information to other relevant staff within your institution. Local IVIg administration protocols may need to be updated to include Kiovig 10%.
As is currently the case, allocation of domestic or imported immunoglobulin products, which will include Kiovig 10%, will be managed within BloodSTAR based on patients’ specific conditions, according to a pre‑determined allocation matrix which is regularly adjusted by the NBA.
Further information in relation to product allocation is available at https://www.criteria.blood.gov.au/SupportingInformation#Allocation.
For product information queries, including access to support materials, please contact Takeda Australia on 1800 012 612 or email medinfoAPAC@takeda.com.
Should you have any queries regarding this change, please contact firstname.lastname@example.org.